Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 160,257 |
|
|||||
| News | - | ||||||
| Day High | 1.39 | Low High |
|||||
| Day Low | 1.32 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| InflaRx NV | IFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.35 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.38 | 1.32 | 1.39 | 1.35 | 1.35 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 611 | 160,257 | $ 1.36 | $ 217,815 | - | 1.14 - 6.15 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:49 | 33 | $ 1.32 | USD |
InflaRx NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 72.51M | 54.12M | - | 20.16M | -29.48M | -0.54 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
InflaRx NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.43 | 1.60 | 1.21 | 1.34 | 190,621 | -0.08 | -5.59% |
| 1 Month | 1.55 | 1.60 | 1.14 | 1.39 | 653,997 | -0.20 | -12.9% |
| 3 Months | 3.92 | 4.15 | 1.14 | 1.71 | 342,110 | -2.57 | -65.56% |
| 6 Months | 4.17 | 4.70 | 1.14 | 2.69 | 271,251 | -2.82 | -67.63% |
| 1 Year | 2.61 | 6.15 | 1.14 | 3.74 | 406,546 | -1.26 | -48.28% |
| 3 Years | 4.24 | 6.88 | 0.7762 | 3.67 | 562,043 | -2.89 | -68.16% |
| 5 Years | 29.14 | 53.10 | 0.7762 | 4.86 | 628,169 | -27.79 | -95.37% |
InflaRx NV Description
| InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
